Structure Guided Design of CCL27 CAR T-Cells Against CCR10 for Multiple Myeloma. Read more about Structure Guided Design of CCL27 CAR T-Cells Against CCR10 for Multiple Myeloma.
Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients. Read more about Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients.
Novel Single-Cell RNA Technology Simplifies Measurement of Anti-BCMA CAR-Ts in Patient Samples. Read more about Novel Single-Cell RNA Technology Simplifies Measurement of Anti-BCMA CAR-Ts in Patient Samples.
Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2. Read more about Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2.
Development of a Dual-Antigen Targeting CAR-T Therapy Directed Against CD70 and Active Integrin ß2 for Acute Myeloid Leukemia. Read more about Development of a Dual-Antigen Targeting CAR-T Therapy Directed Against CD70 and Active Integrin ß2 for Acute Myeloid Leukemia.
Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry. Read more about Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry.
In Vivo and In Vitro Chemical Synthetic Lethality of ABHD17 and MEK Inhibition in NRAS -Mutant Acute Myeloid Leukemia. Read more about In Vivo and In Vitro Chemical Synthetic Lethality of ABHD17 and MEK Inhibition in NRAS -Mutant Acute Myeloid Leukemia.
HLA-Pan-DP CAR-T Demonstrates Cytotoxicity Against Multiple Hematological Malignancies. Read more about HLA-Pan-DP CAR-T Demonstrates Cytotoxicity Against Multiple Hematological Malignancies.
Effective Azacytidine Monotherapy in an Infant with Mosaic NRAS-Driven JMML. Read more about Effective Azacytidine Monotherapy in an Infant with Mosaic NRAS-Driven JMML.
Preclinical Activity of RAS(ON) Multi-Selective Inhibitor RMC-7977 and Therapeutic Combinations in AML with Signaling Mutations. Read more about Preclinical Activity of RAS(ON) Multi-Selective Inhibitor RMC-7977 and Therapeutic Combinations in AML with Signaling Mutations.
